VRTX · Vertex Pharmaceuticals Incorporated
Is VRTX setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Vertex Pharmaceuticals Incorporated, in one place.
Today's breakout radarIs VRTX setting up for a breakout?
Breakout Radar API →VRTX reports earnings on Nov 2, 2026 — a breakout right before a report can reverse on the numbers.
Not today. VRTX is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about VRTX?
Stock Sentiment API →Bulls: Vertex dominates cystic fibrosis and is expanding into pain, gene editing and kidney disease with multiple shots on goal. CASGEVY, the first-ever approved CRISPR-based therapy, is cited alongside clinical data described as stronger than ever, yet $CRSP and $VRTX market caps are said to be smaller than in the preclinical dataset era.
Bears: A bear point flags that Vertex's kidney drug can quietly drain patients' infection-fighting antibodies (IgG); the company's own trial protocol, published with the NEJM paper two days ago, states this plainly as an "expected" effect of the drug, and the trial was built with a hidden element.
Reading from Oct 27, 2026; each post classified by AI, weighted by engagement.
What is the news saying about VRTX?
News Sentiment API →No recent news reading for VRTX. The News Sentiment API reads today's headlines on any US stock.
Are VRTX insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Tatsis Ourania$787K · Jul 2, 2026
- Sold · McKechnie Duncan$800K · Jul 2, 2026
- Sold · Liu Joy$416K · Jul 1, 2026
- Sold · Bozic Carmen$288K · Jun 26, 2026
- Sold · Bozic Carmen$471K · Jun 18, 2026
How is Vertex Pharmaceuticals Incorporated's business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $3.3B | +12% | $1.1B | $4.31 |
| Mar 31, 2026 | $3.0B | +8% | $1.0B | $4.02 |
| Sep 30, 2025 | $3.1B | +11% | $1.1B | $4.20 |
| Jun 30, 2025 | $3.0B | +12% | $1.0B | $3.99 |
From the company's SEC filings (10-Q and 10-K).
What does Vertex Pharmaceuticals Incorporated expect?
Company Guidance API →- Full Year 2026 · total revenue · 8-K filed Aug 3, 2026
“Vertex today raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously.”
- Full Year 2026 · non-cf product revenue · 8-K filed Aug 3, 2026
“Non-CF product revenue Unchanged $0.5 billion or greater”
- Full Year 2026 · combined gaap r&d, aipr&d and sg&a expenses · 8-K filed Aug 3, 2026
“Vertex reiterated its full year 2026 guidance for combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses of $6.3 billion to $6.45 billion and $5.65 billion to $5.75 billion, respectively.”
- Full Year 2026 · combined non-gaap r&d, aipr&d and sg&a expenses · 8-K filed Aug 3, 2026
“Vertex reiterated its full year 2026 guidance for combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses of $6.3 billion to $6.45 billion and $5.65 billion to $5.75 billion, respectively.”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.